AstraZeneca Completes Aspen Agreement

ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO

01 September 2016 07:00 BST

ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO

AstraZeneca today announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics ( Xylocaine/Xylocard/Xyloproct , Marcaine , Naropin , Carbocaine and Citanest ). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company’s financial statements.

* With the exception of Ukraine and Zimbabwe, which are subject to separate closing

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

www.astrazeneca.com     

CONTACTS

  Media Enquiries          
  Neil Burrows     UK/Global     +44 203 749 5637  
  Vanessa Rhodes     UK/Global     +44 203 749 5736  
  Karen Birmingham     UK/Global     +44 203 749 5634  
  Rob Skelding     UK/Global     +44 203 749 5821  
  Jacob Lund     Sweden     +46 8 553 260 20  
  Michele Meixell     US     +1 302 885 2677  
  Investor Relations    
  UK    
  Thomas Kudsk Larsen     +44 203 749 5712   
  Craig Marks     Finance, Fixed Income, M&A     +44 7881 615 764  
  Nick Stone     Respiratory & Autoimmunity     +44 203 749 5716  
  Henry Wheeler     Oncology     +44 203 749 5797  
  Christer Gruvris     Infection & Neuroscience     +44 203 749 5711  
  US    
  Lindsey Trickett     Cardiovascular & Metabolic Diseases     +1 240 543 7970  
  Mitchell Chan     Oncology     +1 240 477 3771  
  Toll-free     +1 866 381 7277  

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links